VRVanessa Rameh

Vanessa Rameh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vanessa Rameh has a total of 141 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pediatric Pleomorphic Xanthoastrocytomas: A Multicenter Neuroradiologic and Clinical Correlation Study

    by Karanjot Chhatwal, Thomas Hargreaves, Francesco Pacchiano, Cesar Alves, Vanessa Rameh, Adam Ezra Goldman-Yassen, Aashim Bhatia, Alok Jaju, Kristen W. Yeom, Jason Nixon, et al.

    Pleomorphic Xanthoastrocytomas (PXAs) are rare pediatric brain tumors accounting for approximately 1% of primary brain neoplasms in children and young adults. Despite recent imaging and molecular advances, gaps remain in our understanding of their diverse imaging characteristics and clinical outcomes. This study provides a large international, multi-institutional analysis of pediatric PXAs focusing on neuroimaging and clinical outcomes. We conducted a retrospective international multi-center study including 63 pediatric patients with histologically confirmed PXAs. Neuroimaging data were reviewed, and molecular analyses were recorded with emphasis on BRAF V600E mutations and CDKN2A/B deletions. Treatment modalities and clinical outcomes, including progression-free and overall survival, were analyzed using statistical survival models. 73.3% of tumors were CNS WHO grade 2 and 26.7% were CNS WHO grade 3. The median age at diagnosis was 10.7 (IQR 6.9) years. CNS WHO grade 3 tumors were significantly larger at diagnosis, with a median volume of 87,920 mm³ compared with 14,925 mm³ for grade 2 tumors (p = 0.03). BRAF V600E mutations were identified in 78% of cases and CDKN2A/B deletions in 93.5%. On MRI, PXAs typically appeared well-defined, with cortical and leptomeningeal contact (86.0% and 56.4%, respectively), frequent cysts (59.6%), and intermediate diffusivity (mean ADC 1005 × 10-6 mm2/s). CT imaging showed most tumors were isointense to gray matter (52.0%), with hydrocephalus more common in grade 3 tumors (71.4% vs. 26.3%, p = 0.07). Gross total resection was achieved in 73.7% of cases and was associated with improved progression-free survival, independent of age at diagnosis and tumor grade (HR = 0.39; 95% CI, 0.16-0.96; p = 0.041). Larger tumor volume correlated with poorer survival outcomes (HR = 3.47; 95% CI, 0.83-14.4; p = 0.087), also independent of tumor grade and age at diagnosis. Tumor recurrence occurred in 44.8% of patients at three years. The estimated three-year overall survival rate was 94.7%. Pediatric PXAs exhibit distinct neuroimaging and molecular features correlating with prognosis. Integrated evaluation of radiological and clinical features is critical to improve risk stratification and guide personalized therapeutic strategies in this rare tumor population.

  • An Emerging Pediatric CNS Tumor: Imaging Evaluation of H3K27M and BRAF V600E Comutated Midline Tumors

    by Vanessa Rameh, Loai Aker, Sridhar Vajapeyam, Alireza Ziaei, Kee Kiat Yeo, Cesar Alves, Lissa C. Baird, Katie P. Fehnel, Karen Wright, Susan Chi, et al.

    BACKGROUND AND PURPOSE: Diffuse midline gliomas (DMG) with concurrent H3K27M and BRAF V600E mutations represent a rare and poorly studied subset of pediatric central nervous system tumors. While traditionally associated with poor prognosis, recent evidence suggests that MAPK pathway alterations may confer improved outcomes in select cases. This study aims to explore the imaging characteristics of H3K27M/BRAF V600E coaltered midline gliomas. MATERIALS AND METHODS: Eight pediatric patients (6 males, 2 females; age range: 3–18 years, mean: 11 years) with H3K27M/BRAFV600E-mutant midline tumors were retrospectively reviewed. Data collected included MR imaging features, histopathologic and molecular data, treatment, and follow-up outcomes. RESULTS: Of the eight patients identified, six (n=6/8; 75%) were thalamic, with the remainder involving the hypothalamus/optic pathway and cervical spine. Tumors demonstrated heterogeneous histology: pediatric-type low-grade glioma-like (n=3), ganglioglioma-like (n=3), and high-grade glioma-like (n=2). All tumors were midline in location. Thalamic tumors were well-demarcated but demonstrated infiltrative and exophytic components, with frequent involvement of the third ventricle (n=4/6;66.7%) and internal capsule (n=4/6;66.7%). Imaging demonstrated heterogeneous T1/T2 signal with coarse calcifications in five of thalamic tumors. Hydrocephalus was present in all patients with thalamic lesions. These tumors demonstrated varied diffusion characteristics with areas of intermediate and reduced diffusivity. Enhancement was present but heterogeneous across tumor types. Both HGG-like tumors presented with cranial and spinal leptomeningeal metastases. CONCLUSIONS: DMGs harboring both H3K27M and BRAFV600E mutations may represent a distinct subtype, with radiologic, histopathologic, and molecular features that appear different from those of non-MAPK–altered H3K27M DMGs. ABBREVIATIONS: World Health Organization = WHO, Diffuse midline glioma = DMG, Mitogen-activated protein kinase = MAPK, Formalin-fixed paraffin-embedded = FFPE, Wild-type = WT, Overall survival = OS, Contrast-enhanced = CE, High-grade gliomas = HGGs, Long-term survival = LTS, Short-term survival= STS


  • 7T TOF-MRA in Adolescents

    by Sergio Valencia, Fedel Machado-Rivas, Maria Camila Cortes-Albornoz, Samuel Cartmell, Harry Griffin, Darren B. Orbach, Vanessa Rameh, Alfred Pokmeng See, Simon K. Warfield, Onur Afacan, et al.

    The increased signal-to-noise ratio (SNR) at 7 Tesla (7T) enables higher spatial resolution for neurovascular imaging, yet its application in pediatric magnetic resonance angiography (MRA) remains underexplored. This study systematically evaluates the advantages of 7T time-of-flight (TOF) MRA compared to 3T in pediatric patients, hypothesizing that 7T would provide superior vessel contrast and increased vascular volume, given the use of smaller voxels, as well as higher SNR, despite these smaller voxels. This HIPAA-compliant, IRB-approved retrospective study included pediatric patients (<19 years) who underwent 7T TOF MRA. Controls consisted of either same-subject 3T MRAs within 6 months (when available) or age-and sex-matched 3T MRA subjects. Imaging parameters were optimized for spatial resolution at 7T to achieve 0.3-0.4 mm isotropic voxels. Quantitative analysis included contrast ratio (CR) and SNR measurements for the ICA, M1 to M4 arterial segments, and lenticulostriate perforating arteries. Vascular volume was assessed using 3D segmentation. Semiquantitative vessel conspicuity ratings and motion artifact scoring were performed by blinded neuroradiologists. Fifteen patients (10 with 7T MRA, 5 with matched 3T controls) and 20 MRAs were analyzed. CR was significantly higher at 7T for perforators, M3, and M4 branches (P < 0.05), with the greatest improvement in M4 branches. Vascular volume was 147% greater at 7T (P = 0.018), reflecting improved small vessel depiction and segmentation. Semiquantitative analysis showed significantly better vessel conspicuity at 7T for M4 branches and lenticulostriate perforators (P < 0.01). Motion artifact scores were similar between field strengths (P = 0.118). 7T TOF MRA significantly enhances vascular contrast and improves visualization of small arteries compared to 3T, making it a valuable tool for pediatric cerebrovascular imaging. CR= Contrast Ratio; LSA= Lenticulostriate Perforating Arteries.


  • Postradiation MR Imaging Features in Molecular and Mutational Analyses in Pontine Pediatric Diffuse Midline Gliomas

    by Vanessa Rameh, Alireza Ziaei, Sridhar Vajapeyam, Nan Chen, Wendy B. London, Karen Wright, Tina Y. Poussaint

    BACKGROUND AND PURPOSE: We aimed to describe the post-radiation imaging features in children with pontine pediatric diffuse midline glioma, and to identify associations between these changes and histone mutational status, as well as overall survival. MATERIALS AND METHODS: Patients were recruited as part of an IRB approved, multicenter clinical trial: Molecularly Determined Treatment of pontine diffuse midline glioma. Subjects had baseline MR imaging that showed classic imaging criteria of pontine diffuse midline glioma and post radiation imaging at regular intervals. All patients underwent biopsy before therapy initiation and received standard radiation therapy with adjuvant bevacizumab. Patients were subsequently stratified based on methylation status and EGFR expression in the biopsy specimen. Imaging analyses included post-radiation T2/FLAIR and enhancing tumor volumes, as well as normalized ADC (nADC) histogram metrics (mean, median, mode, skewness, and kurtosis) at 2 and 4 months post-radiation. The mutation sub-groups were compared using a Wilcoxon rank-sum test. RESULTS: Forty-one patients met eligibility criteria, and mutational status was identified in 35. The median age was 6 years (range: 1.2-17). Seventeen of 35 (49%) had H3-3A histone mutations, 10/35 (29%) had H3C2/3, and 8/35 (22%) were wild type (WT). Except for enhancing volume at RT2, all imaging features had a statistically significant change (pH3C2/3 had statistically significantly higher mean nADC_FLAIR (p=0.05), mode nADC_FLAIR (p=0.003), median nADC_FLAIR (p=0.02), and mode nADC-enhancement (p=0.04) than patients with H3-3A at RT1. These nADC histogram metrics were not statistically significantly different at RT2. Moreover, we found no statistically significant difference in ADC histogram metrics post radiation, when we compared H3-mutant versus WT tumors. CONCLUSIONS: Post-radiation MR imaging features are differentially correlated with the underlying mutational status of pediatric pontine diffuse midline glioma. ABBREVIATIONS:Pediatric pontine diffuse midline glioma=pDMG Diffuse intrinsic pontine glioma= DIPG Epidermal growth factor receptor=EGFR Overall survival=OS Radiotherapy=RT Progression-free survival=PFS Contrast-enhanced=CE Post-radiation time point 1 (2 months post-radiation)=RT1 Post-radiation time point 2 (4 months post-radiation)=RT2


  • Cortically Based Brain Tumors in Children: A Decision-Tree Approach in the Radiology Reading Room

    by Vanessa Rameh, Ulrike Löbel, Felice D’arco, Aashim Bhatia, Kshitij Mankad, Tina Y. Poussaint, Cesar A. Alves

    Cortically-based brain tumors in children constitute a unique set of tumors with variably aggressive biological behavior. As radiologists play an integral role on the multidisciplinary medical team, a clinically useful and easy-to-follow flowchart for the differential diagnoses of these complex brain tumors is essential. This proposed algorithm tree provides the latest insights into the typical imaging characteristics and epidemiologic data that differentiate the tumor entities, taking into perspective the 2021 World Health Organization9s classification and highlighting classic as well as newly identified pathologic subtypes using current molecular understanding. ABBREVIATIONS: Astroblastoma=AB) Angiocentric glioma (AG) Atypical teratoid rhabdoid tumor (ATRT) Central Nervous System tumor (CNS) CNS neuroblastoma FOXR2-activated (NB-FOXR2) Desmoplastic infantile glioma/astrocytoma (DIG/DIA) Diffuse hemispheric glioma, H3 G34-mutant (DHG) Diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters (DGONC) Dysembryoplastic neuroepithelial tumor (DNET) Embryonal Tumors with Multilayered Rosettes (ETMR) Ependymoma (EP) Focal cortical dysplasia (FCD) Ganglioglioma/gangliocytoma (GG) Infant-type hemispheric glioma (IHG) Intracranial pressure (ICP) Long-term epilepsy-associated tumors (LEATs) Pediatric diffuse low-grade gliomas (pLGG) MR spectroscopy (MRS) Multinodular and vacuolating neuronal tumor (MVNT) Overall survival (OS) Pediatric diffuse high-grade gliomas (pHGG)


  • Morning Glory Disc Anomaly: Expanding the MR Phenotype

    by F.D. Firouzabadi, M D Soldatelli, V. Rameh, G. Heidary, S.O. Vargas, E. Gonzalez, J. Rispoli, R. Rahbar, C.D. Robson

    BACKGROUND AND PURPOSE: Morning glory disc anomaly (MGDA) is a congenital malformation characterized by a funnel-shaped optic disc excavation with radiating vessels and a central glial tuft. Imaging is essential to evaluate associated cephalocele and steno-occlusive vasculopathy. The goal of this study was to assess optic nerve, chiasmatic, and sphenoid bone morphology in MGDA. MATERIALS AND METHODS: This retrospective study examined all subjects with funduscopically confirmed MGDA diagnosed and imaged with brain MR imaging between 2008 and 2023. RESULTS: Thirty-two children met inclusion criteria. Ocular involvement was unilateral in 29 subjects and bilateral in 3. Segmental optic nerve enlargement ipsilateral to the MGDA was seen in 21 subjects, with 3 also demonstrating a segmental reduction in the size of the ipsilateral optic nerve. Segmental reduction in the size of the ipsilateral optic nerve was present in 3 additional subjects, one with bilateral MGDA. The optic chiasm appeared asymmetrically thickened in 21 subjects, often with deformity. The optic nerves appeared normal in signal intensity in all subjects, with faint peripheral chiasmatic enhancement in 4 of 20 patients who received contrast. Optic nerve findings were stable in 15 subjects with multiple examinations. A persistent craniopharyngeal canal was identified in 17 subjects with sphenoid cephalocele in 1 and mild inferior pituitary gland displacement in 4. Tubular or nodular nasopharyngeal lesions were seen in 10 subjects. One subject had an off-midline sphenoid bone cleft, midbrain deformity, and abnormal thickening of and enhancement around the left oculomotor nerve; the oculomotor nerve finding was present in 1 additional patient. CONCLUSIONS: MGDA often manifests with ipsilateral optic nerve thickening, leading to a potential misdiagnosis as optic glioma. MGDA is also commonly associated with a persistent craniopharyngeal canal with variable pituitary gland and infundibular deformity, cephalocele, and tubular or nodular nasopharyngeal lesions.


  • Open Access

    Prevalence and risk factors for atypical femoral fracture among Lebanese patients with hip and shaft fractures

    by Abir Bou Khalil, Ryan Yammine, Vanessa Rameh, Catherina Zadeh, Randa Saad, Hasan Mallah, Nabil J Khoury, Ghada El-Hajj Fuleihan

    This retrospective study investigates the prevalence of atypical femoral fractures (AFFs) among patients admitted with hip and shaft fractures at a tertiary referral center in Beirut, Lebanon. We analyzed electronic medical records and radiology studies of patients aged above 40 admitted with hip and shaft fractures between January 2006 and December 2019. Fractures were confirmed by ICD9 or ICD10 codes. All cases were reviewed by radiologists, and AFFs were identified according to the 2013 revised ASBMR criteria. We identified 1366 hip and shaft fracture patients, of which 14 female patients had 19 AFFs. This represents a prevalence of 1.0% among all hip and shaft fractures patients and 1.7% among all female hip and shaft fracture patients. Bilateral AFFs were found in 5 of the 14 patients. Patients with AFF tended to be younger, with a mean age of 74.3 (±8.6) yr compared to 78.0 (±10.6) for patients with non-AFF fractures. A total of 36% of AFF patients had a prior history of non-traumatic fracture at first admission. A high percentage of patients with AFFs reported intake of proton pump inhibitors (42.9%) and glucocorticoids (21.4%). Bisphosphonate exposure was noted in 64.3% of AFF patients. None of the AFF patients were active smokers or consumed alcohol regularly. BMD assessments were available for 7 AFF patients, indicating osteoporosis in 4 and osteopenia in 3 cases. Hip axis length measurements showed no significant difference between AFF patients (N = 7) and sex and age-matched controls (N = 21). The study underlines the prevalence and characteristics of AFFs in Lebanon, which is consistent with the numbers reported in the literature (0.32%–5%). A larger prospective study that includes hospitals across the nation is needed to gain a more comprehensive view of the prevalence of AFFs in the Lebanese population.


  • Open Access

    Early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy: a multicentre double-blind pilot randomised controlled trial

    by Reema Garegrat, Atul Londhe, Swati Manerkar, Sudhindrashayana Fattepur, Laxmikant Deshmukh, Amol Joshi, Savitha Chandriah, Mallesh Kariyappa, Sahana Devadas, Theranirajan Ethirajan, et al.

    Objective To examine the feasibility of early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy (HIE). Design Double-blind pilot randomised controlled trial. Setting Eight neonatal units in South Asia. Patients Neonates (≥36 weeks) with moderate or severe HIE admitted between 31 December 2022 and 3 May 2023. Interventions Erythropoietin (500 U/kg daily) or to the placebo (sham injections using a screen) within 6 hours of birth and continued for 9 days. MRI at 2 weeks of age. Main outcomes and measures Feasibility of randomisation, drug administration and assessment of brain injury using MRI. Results Of the 154 neonates screened, 56 were eligible; 6 declined consent and 50 were recruited; 43 (86%) were inborn. Mean (SD) age at first dose was 4.4 (1.2) hours in erythropoietin and 4.1 (1.0) hours in placebo. Overall mortality at hospital discharge occurred in 5 (19%) vs 11 (46%) (p=0.06), and 3 (13%) vs 9 (40.9%) (p=0.04) among those with moderate encephalopathy in the erythropoietin and placebo groups. Moderate or severe injury to basal ganglia, white matter and cortex occurred in 5 (25%) vs 5 (38.5%); 14 (70%) vs 11 (85%); and 6 (30%) vs 2 (15.4%) in the erythropoietin and placebo group, respectively. Sinus venous thrombosis was seen in two (10%) neonates in the erythropoietin group and none in the control group. Conclusions Brain injury and mortality after moderate or severe HIE are high in South Asia. Evaluation of erythropoietin monotherapy using MRI to examine treatment effects is feasible in these settings. Trial registration number NCT05395195.


  • Open Access

    Correlation between Multiparametric MR Imaging and Molecular Genetics in Pontine Pediatric High-Grade Glioma

    by V. Rameh, S. Vajapeyam, A. Ziaei, P. Kao, W.B. London, S.J. Baker, J. Chiang, J. Lucas, C.L. Tinkle, K.D. Wright, et al.

    BACKGROUND AND PURPOSE: Molecular profiling is a crucial feature in the “integrated diagnosis” of CNS tumors. We aimed to determine whether radiomics could distinguish molecular types of pontine pediatric high-grade gliomas that have similar/overlapping phenotypes on conventional anatomic MR images. MATERIALS AND METHODS: Baseline MR images from children with pontine pediatric high-grade gliomas were analyzed. Retrospective imaging studies included standard precontrast and postcontrast sequences and DTI. Imaging analyses included median, mean, mode, skewness, and kurtosis of the ADC histogram of the tumor volume based on T2 FLAIR and enhancement at baseline. Histone H3 mutations were identified through immunohistochemistry and/or Sanger or next-generation DNA sequencing. The log-rank test identified imaging factors prognostic of survival from the time of diagnosis. Wilcoxon rank-sum and Fisher exact tests compared imaging predictors among groups. RESULTS: Eighty-three patients had pretreatment MR imaging and evaluable tissue sampling. The median age was 6 years (range, 0.7–17 years); 50 tumors had a K27M mutation in H3-3A, and 11, in H3C2/3. Seven tumors had histone H3 K27 alteration, but the specific gene was unknown. Fifteen were H3 wild-type. Overall survival was significantly higher in H3C2/3- compared with H3-3A-mutant tumors (P = .003) and in wild-type tumors compared with any histone mutation (P = .001). Lower overall survival was observed in patients with enhancing tumors (P = .02) compared with those without enhancement. H3C2/3-mutant tumors showed higher mean, median, and mode ADC_total values (P < .001) and ADC_enhancement (P < .004), with lower ADC_total skewness and kurtosis (P < .003) relative to H3-3A-mutant tumors. CONCLUSIONS: ADC histogram parameters are correlated with histone H3 mutation status in pontine pediatric high-grade glioma.


  • The added value of skeletal surveys in the initial evaluation of children diagnosed with Langerhans cell histiocytosis in the era of staging 18F‐FDG PET/CT: A retrospective study

    by Vanessa Rameh, Stephan Voss, M. Alejandra Bedoya, Danielle Beaulieu, Da Zhang, Barbara A. Degar, Andy Tsai

    Objective: Currently, there is no consensus protocol on the initial staging evaluation for Langerhans cell histiocytosis (LCH). Our institutional protocol consists of a skeletal survey and a whole‐body positron emission tomography with 2‐deoxy‐2‐[fluorine‐18] fluoro‐D‐glucose integrated with computed tomography (FDG PET/CT) study. The utility of the PET/CT lies in its sensitivity in detecting osseous and extra‐osseous lesions, and in determining the baseline metabolic activity of LCH lesions to assess treatment response. However, the added utility of the skeletal survey in staging LCH is unclear. Therefore, this study retrospectively assessed the added diagnostic value of skeletal surveys in patients with baseline PET/CTs for initial staging of LCH.Methods: We retrospectively searched the medical records of all patients less than or equal to 18 years old at a large children's hospital (May 2013 to September 2021). The inclusion criteria were (a) biopsy‐proven diagnosis of LCH and (b) initial staging PET/CT and skeletal survey performed less than or equal to 1 month apart. A blinded pediatric radiologist reviewed the skeletal surveys and another reviewed the PET/CTs in identifying LCH osseous lesions.Results: Our study cohort consisted of 49 children with 86 LCH osseous lesions. In non‐extremity locations, PET/CT identified 70/70 (100%) osseous lesions, while skeletal surveys detected 43/70 (61.4%) osseous lesions. In the extremities, PET/CT identified 13/16 (81.3%) osseous lesions, while skeletal surveys detected 15/16 (93.8%) osseous lesions.Conclusion: Skeletal surveys increased the detection rate of osseous lesions in the extremities, but added no diagnostic value to the detection of osseous lesions in non‐extremity locations. Therefore, we propose to abbreviate the skeletal survey to include only extremity radiographs.